This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral
pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2
mutant, non-enhancing glioma.
- This research study involves an experimental treatment called Niraparib.